Denmark-based, Tetra Pharm Technologies (TPT) is a biotech startup committed to treat neuropathic pain & mental health disorders, by “designing & developing new drug formulations/ candidates, conducting clinicals & commercializing medicines targeting the endocannabinoid system (ECS)”. <Quick primer on the ECS: it regulates & controls many critical body functions such as, via CB1 receptors (found mostly in the brain) – learning & memory, emotional processing, sleep, temperature control, pain control, & via CB2 receptors (found mostly in tissue) – inflammatory & immune responses [note: CB2 receptors are particularly exciting targets for drug development because they don’t cause the “high” (an often unwanted side effect) that stimulating the CB1 receptor (with cannabis) does]>. Worth keeping mind, the European market for cannabinoid-based treatment is expected to reach €3.2b by 2025. TPT is said to have closed “several significant distribution deals” across main European markets & intends to use the new funds to release its first product (to treat neuropathic pain) this year. “We exist to improve the lives of patients & their families, by formulating efficient drugs, with a low side-effect profile, at a fair price”. Tetra Pharm Technologies was founded in 2020 by Martin Rose (CEO) & Jesper Breum and employs <10 people. <Source: articstartup.com, finsmes.com, prnewswire.co.uk, pharmacos-media.fr>
